Results 31 to 40 of about 1,652 (181)

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations

Frontiers in Medicine, 2021
p53 is among the most frequently mutated tumor suppressor genes given its prevalence in >50% of all human cancers. One critical tumor suppression function of p53 is to regulate transcription of downstream genes and maintain genomic stability by ...
Xiangbing Meng, Xiangbing Meng, Jason Z. Gao, Sean Michael T. Gomendoza, John W. Li, John W. Li, Shujie Yang, Shujie Yang   +7 more
doaj   +1 more source

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair

Neoplasia: An International Journal for Oncology Research, 2015
To improve the efficacy of chemoradiation therapy for locally advanced pancreatic cancer and begin to establish patient selection criteria, we investigated the combination of the WEE1 inhibitor AZD1775 with gemcitabine-radiation in homologous ...
Tasneem Kausar, Jason S. Schreiber, David Karnak, Leslie A. Parsels, Joshua D. Parsels, Mary A. Davis, Lili Zhao, Jonathan Maybaum, Theodore S. Lawrence, Meredith A. Morgan   +9 more
doaj   +1 more source

WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma

Therapeutic Advances in Hematology, 2020
Background: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, characterized by high levels of genomic instability and the activation of DNA damage repair pathways.
Mathilde R. W. de Jong, Myra Langendonk, Bart Reitsma, Pien Herbers, Monique Lodewijk, Marcel Nijland, Anke van den Berg, Emanuele Ammatuna, Lydia Visser, Tom van Meerten   +9 more
doaj   +1 more source

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC

Cell Reports, 2022
Summary: Small cell lung cancers (SCLCs) have high mutational burden but are relatively unresponsive to immune checkpoint blockade (ICB). Using SCLC models, we demonstrate that inhibition of WEE1, a G2/M checkpoint regulator induced by DNA damage ...
Hirokazu Taniguchi, Rebecca Caeser, Shweta S. Chavan, Yingqian A. Zhan, Andrew Chow, Parvathy Manoj, Fathema Uddin, Hidenori Kitai, Rui Qu, Omar Hayatt, Nisargbhai S. Shah, Álvaro Quintanal Villalonga, Viola Allaj, Evelyn M. Nguyen, Joseph Chan, Adam O. Michel, Hiroshi Mukae, Elisa de Stanchina, Charles M. Rudin, Triparna Sen   +19 more
doaj   +1 more source

Discovery of potential WEE1 inhibitors via hybrid virtual screening

Frontiers in Pharmacology, 2023
G2/M cell cycle checkpoint protein WEE1 kinase is a promising target for inhibiting tumor growth. Although various WEE1 inhibitors have entered clinical investigations, their therapeutic efficacy and safety profile remain unsatisfactory.
Tingting Jin, Wei Xu, Roufen Chen, Liteng Shen, Jian Gao, Lei Xu, Xinglong Chi, Nengming Lin, Lixin Zhou, Zheyuan Shen, Bo Zhang   +10 more
doaj   +1 more source

Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint

Journal of Experimental & Clinical Cancer Research, 2018
Background Targeting poly ADP-ribose polymerase (PARP) has been recently identified as a promising option against gastric cancer (GC). However, PARP inhibitors alone achieve limited efficacy.
Xiaoting Lin, Dongshao Chen, Cheng Zhang, Xiaotian Zhang, Zhongwu Li, Bin Dong, Jing Gao, Lin Shen   +7 more
doaj   +1 more source

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors

Frontiers in Oncology, 2021
Despite the success of antiestrogens in extending overall survival of patients with estrogen receptor positive (ER+) breast tumors, resistance to these therapies is prevalent.
Yassi Fallah, Diane M. Demas, Lu Jin, Wei He, Ayesha N. Shajahan-Haq   +4 more
doaj   +1 more source

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

Therapeutic Advances in Medical Oncology, 2020
Background: PARP inhibitor (PARPi) monotherapy is a new strategy in BRCA germ-line deficient triple negative breast cancer (TNBC). However, not all patients respond, and the development of resistance limits the use of PARPi monotherapy.
Reem Ali, Adel Alblihy, Michael S. Toss, Mashael Algethami, Rabab Al Sunni, Andrew R. Green, Emad A. Rakha, Srinivasan Madhusudan   +7 more
doaj   +1 more source

Strategies for Targeted Therapy in Head and Neck Squamous Cell Carcinoma Using WEE1 Inhibitor AZD1775 [PDF]

JAMA Otolaryngology–Head & Neck Surgery, 2017
This study maps the cellular response to the WEE1 inhibitor and explores the contributions of p53 to its effect.
Michael, Kao, Carlos, Green, Julia, Sidorova, Eduardo, Méndez   +3 more
openaire   +2 more sources

Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer

Scientific Reports, 2019
Although the concurrent use of a chemotherapeutic agent and radiotherapy improves survival in patients with locally advanced or recurrent cervical cancer, severe side effects related to chemotherapy are frequent and may result in a low quality of life ...
Yoo-Young Lee, Young-Jae Cho, Sung-won Shin, Changhoon Choi, Ji-Yoon Ryu, Hye-Kyung Jeon, Jung-Joo Choi, Jae Ryoung Hwang, Chel Hun Choi, Tae-Joong Kim, Byoung- Gie Kim, Duk-Soo Bae, Won Park, Jeong-Won Lee   +13 more
doaj   +1 more source